Recombinant Measles Virus for Waterborne Pathogen Detection and Treatment

Publication ID: 24-11857616_0007_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Recombinant Measles Virus for Waterborne Pathogen Detection and Treatment,” Published Technical Disclosure No. 24-11857616_0007_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857616_0007_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,616.

Summary of the Inventive Concept

A novel system utilizing a recombinant measles virus expressing Zika virus prM and E proteins for detecting and monitoring waterborne pathogens, treating wastewater, and preventing Zika virus transmission in mosquitoes and agricultural settings.

Background and Problem Solved

The original patent disclosed a recombinant measles virus expressing Zika virus prM and E proteins for vaccine development. However, this technology has limitations in addressing the growing concern of waterborne pathogens and Zika virus transmission in non-human settings. The new inventive concept addresses these limitations by applying the core technology to an entirely different industry, field, or problem, providing a novel solution for waterborne pathogen detection, wastewater treatment, and Zika virus prevention.

Detailed Description of the Inventive Concept

The inventive concept comprises a recombinant measles virus expressing Zika virus prM and E proteins, engineered to target and bind to specific waterborne pathogens, facilitating their detection and removal from wastewater. The system can be used for monitoring and tracking the spread of Zika virus in agricultural settings, and for treating and preventing Zika virus transmission in mosquitoes. The recombinant measles virus can be immobilized on a surface to create a biosensor for detecting Zika virus in food products, providing a rapid and accurate detection method.

Novelty and Inventive Step

The new claims introduce a novel application of the recombinant measles virus technology, expanding its use beyond vaccine development to address waterborne pathogen detection, wastewater treatment, and Zika virus prevention. The inventive step lies in the engineering of the prM and E proteins to target specific waterborne pathogens, and the development of a system for detecting and monitoring these pathogens in various settings.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept include the use of different viral vectors, such as adenovirus or lentivirus, to express the Zika virus prM and E proteins. Variations of the system could include the use of different detection methods, such as PCR or ELISA, and the development of portable or handheld biosensors for on-site detection.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the water treatment, agricultural, and food safety industries. The system could be marketed as a solution for detecting and monitoring waterborne pathogens, treating wastewater, and preventing Zika virus transmission in mosquitoes and agricultural settings. The biosensor component could be marketed as a rapid and accurate detection method for Zika virus in food products.

CPC Classifications

SectionClassGroup
A A61 A61K39/12
C C07 C07K14/005
C C12 C12N7/00
A A61 A61K2039/5254
A A61 A61K2039/53
C C12 C12N2760/18421
C C12 C12N2760/18423
C C12 C12N2770/24122
C C12 C12N2770/24123
C C12 C12N2770/24134

Field of Art

Virology, molecular biology, and vaccine development, with specific expertise in recombinant viral vector technologies, protein engineering, and pathogen detection systems

Person of Ordinary Skill (PHOSITA) Profile

A skilled researcher with advanced degrees in molecular biology or virology, experienced in genetic engineering of viral vectors, protein modification techniques, and understanding of viral protein interactions

Obviousness Rationale

A person of ordinary skill would recognize the natural extension of the source patent's recombinant measles virus technology to alternative applications beyond vaccine development. The core technical elements of expressing Zika virus prM and E proteins in a measles virus vector provide a versatile platform that can be readily adapted to detection, monitoring, and treatment applications. The PTD's variations represent predictable and logical extensions of the foundational viral vector technology disclosed in the source patent.

Obvious Combinations & Variations

Source Patent Element
Recombinant measles virus expressing Zika virus prM and E proteins for vaccine development
PTD Variation
Using the same viral vector for waterborne pathogen detection and biosensor applications
Obviousness Reasoning
A PHOSITA would recognize that viral vectors can be easily repurposed for detection and diagnostic applications, representing a known technique in molecular biology for expanding technological utility
Source Patent Element
Genetic optimization of viral protein expression for specific host systems
PTD Variation
Engineering prM and E proteins to target specific waterborne pathogens and insect vectors
Obviousness Reasoning
Protein engineering to modify targeting capabilities is a standard approach in virology, representing a predictable modification of existing viral vector technologies
Source Patent Element
Measles virus vector system for expressing foreign viral proteins
PTD Variation
Developing a system for tracking and preventing Zika virus transmission in mosquito populations
Obviousness Reasoning
Extending viral vector applications to population-level intervention is a logical and foreseeable extension of existing recombinant virus technologies
Source Patent Element
Genetic manipulation of viral proteins for improved functionality
PTD Variation
Immobilizing viral proteins on surfaces to create biosensors for pathogen detection
Obviousness Reasoning
Surface immobilization of viral proteins is a well-known technique in biotechnology, representing a predictable method of expanding diagnostic capabilities
Source Patent Element
Expressing viral proteins in a recombinant measles virus vector
PTD Variation
Using alternative viral vectors like adenovirus or lentivirus for similar protein expression
Obviousness Reasoning
Selecting alternative viral vectors for protein expression is a routine design choice for a PHOSITA familiar with viral vector technologies
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857616 and the disclosed variations, a person of ordinary skill in the art would find the claimed innovations obvious and lacking inventive step. The fundamental viral vector technology and protein expression methods described in the source patent provide sufficient technical foundation to render the proposed applications of waterborne pathogen detection, biosensing, and vector intervention predictable and non-innovative extensions of existing recombinant virus technologies.

Original Patent Information

Patent NumberUS 11,857,616
TitleRecombinant measles virus expressing zika virus prM and E proteins
Assignee(s)CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Institut Pasteur